Eyenovia Initiates Process To Explore Strategic Alternatives To Maximize Shareholder Value
Eyenovia Initiates Process To Explore Strategic Alternatives To Maximize Shareholder Value
Eyenovia啓動了探索戰略替代方案的進程，以最大限度地提高股東價值
The company announced its plans for accelerating development of its potential multi-billion dollar product for pediatric progressive myopia (MicroPine). In conjunction with the strategic process and focus on its late stage MicroPine asset, Eyenovia reiterated its immediate commercialization opportunities and corporate savings intended to reduce operating expenses while continuing to support meaningful value generation from the company's two FDA-approved products.
該公司宣佈計劃加速開發其潛在的數十億美元兒童進行性近視產品（MicroPine）。結合戰略流程和專注於其後期的MicroPine資產，Eyenovia重申了其直接的商業化機會和企業儲蓄，旨在減少運營開支，同時繼續支持該公司兩款獲得美國食品藥品管理局批准的產品創造有意義的價值。